Acute renal failure in a pediatric kidney allograft recipient treated with intravenous immunoglobulin for parvovirus B19 induced pure red cell aplasia

2005 ◽  
Vol 9 (6) ◽  
pp. 801-804 ◽  
Author(s):  
Mihail M. Subtirelu ◽  
Joseph T. Flynn ◽  
Richard S. Schechner ◽  
James M. Pullman ◽  
Dianne Feuerstein ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Intravenous Immunoglobulin ◽  
Parvovirus B19 ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Kidney Allograft ◽  
Red Cell Aplasia

scholarly journals Pure red cell aplasia caused by Parvo B19 virus in a kidney transplant recipient

2012 ◽  
Vol 52 (186) ◽  
Author(s):  
A Baral ◽  
B Poudel ◽  
R K Agrawal ◽  
R Hada ◽  
S Gurung
Keyword(s):  
Bone Marrow ◽  
Transplant Recipient ◽  
Intravenous Immunoglobulin ◽  
Kidney Transplant ◽  
Parvovirus B19 ◽  
Kidney Transplant Recipient ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Erythroid Progenitor ◽  
Red Cell Aplasia

Parvo B19 is a single stranded DNA virus, which typically has affi nity for erythroid progenitor cells in the bone marrow and produces a severe form of anemia known as pure red cell aplasia. This condition is particularly worse in immunocompromised individuals. We herein report a young Nepali male who developed severe and persistent anaemia after kidney transplantation while being on immunosuppressive therapy. His bone marrow examination revealed morphological changes of pure red cell aplasia, caused by parvovirus B19. The IgM antibody against the virus was positive and the virus was detected by polymerase chain reaction in the blood. He was managed with intravenous immunoglobulin. He responded well to the treatment and has normal hemoglobin levels three months post treatment. To the best of our knowledge, this is the fi rst such case report from Nepal. Keywords: Intravenous immunoglobulin, kidney transplant recipient, Parvovirus B19, pure red cell aplasia.

scholarly journals Parvovirus B19 Infection due to over Immunosuppression in Kidney Transplant Recipients: Case Reports and Literature Review

2021 ◽  
Vol 2021 ◽  
pp. 1-5
Author(s):  
Abdulrahman Altheaby ◽  
Malak Alotaibi ◽  
Nuha Alajlan ◽  
Ala Alshareef ◽  
Mohammed Alruwaymi ◽  
...  
Keyword(s):  
Intravenous Immunoglobulin ◽  
Kidney Transplant ◽  
Case Reports ◽  
Parvovirus B19 ◽  
Pure Red Cell Aplasia ◽  
Immunocompromised Patients ◽  
Red Cell ◽  
Kidney Transplant Recipients ◽  
Red Cell Aplasia ◽  
Immunosuppressive Medication

Parvovirus B19 (PB19) is a single-stranded DNA virus that belongs to the Erythrovirus genus within the Parvoviridae family. Clinical presentations associated with PB19 infection vary greatly, depending on the infected individual’s age and hematologic and immunologic status. The limited data available regarding consensus on screening algorithms and indications in donors and recipients prior to kidney transplantation makes diagnosis and management challenging. We presented 3 cases of pure red cell aplasia due to parvovirus B19 after kidney transplant. These patients were diagnosed with severe normocytic, normochromic anemia (hemoglobin below 60 g/L) in the 1st 6 months posttransplant. A complete anemia work-up revealed low reticulocyte count and was otherwise inconclusive. All patients were diagnosed with pure red cell aplasia due to parvovirus B19. Two patients improved after receiving intravenous immunoglobulin 2 gm/kg given over 4 doses. Unfortunately, they relapse after few weeks and required additional doses of intravenous immunoglobulin in conjugation with reduction of their immunosuppressive medication. The third patient improved after holding mycophenolate mofetil (MMF) and did not require intravenous immunoglobulin. Whereas PB19 infection is typically self-limiting and associated with positive IgM serology in immunocompetent hosts, these cases highlight the importance of considering PB19 infection in the differential diagnosis of persistent anemia in immunocompromised patients and the challenges in confirming the diagnosis. Intravenous immunoglobulin (IVIG) can be an effective treatment in immunocompromised patients with primary or relapsed PB19 infection in conjunction with minimizing immunosuppressive medication. Further research and consideration are required to determine appropriate and targeted screening in donors and recipients in the peritransplantation period.

Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab

Blood ◽  
2000 ◽  
Vol 96 (3) ◽  
pp. 1184-1186 ◽  
Author(s):  
Vivek R. Sharma ◽  
Donald R. Fleming ◽  
Stephen P. Slone
Keyword(s):  
Monoclonal Antibody ◽  
B Lymphocytes ◽  
Parvovirus B19 ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Humoral Immune ◽  
Red Cell Aplasia ◽  
Point Of Interest ◽  
Humoral Immune System ◽  
Parvovirus B19 Infection

Abstract Rituximab is a chimeric monoclonal antibody directed against CD20 and used in the treatment of B-cell non-Hodgkin's lymphoma. Due to its ability to deplete B lymphocytes, rituximab can interfere with humoral immunity, causing it to be suppressed for several months after treatment. The reported case depicts a serious consequence of this effect of rituximab therapy: pure red cell aplasia resulting from chronic parvovirus B19 infection. The point of interest in this case is not only the association between rituximab therapy and pure red cell aplasia, but the diagnostic and therapeutic utility of the knowledge of parvovirus B19 as the likely etiologic link between the two. Given the known efficacy of intravenous immunoglobulin (IVIg) in the treatment of chronic parvovirus B19 infection, this therapy can cure some of these patients and successfully render most others transfusion-independent until recovery of their own humoral immune system.

scholarly journals Pure red cell aplasia due to parvovirus B19 in pediatric malignancies – a report of two cases

2017 ◽  
Vol 2 (2) ◽  
pp. S19-S20
Author(s):  
Putun Patel ◽  
Vibha Bafna ◽  
Sandip Bartakke ◽  
Priya Gupta ◽  
Sanjay Mankar ◽  
...  
Keyword(s):  
Parvovirus B19 ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Pediatric Malignancies ◽  
Red Cell Aplasia
Sign in / Sign up

Export Citation Format

Share Document